Graham Pawelec Biosketch
Graham Pawelec received an MA in Natural Sciences in 1978 and a PhD in Transplantation Immunology in 1982 from the University of Cambridge, UK, and the Dr.
habil and Venia Legendi from the University of Tübingen, Germany, where he became Professor of Experimental Immunology in 1997. He was affiliated with the Center for Medical Research, University
of Tübingen Medical School, until April 2019.
His research interests are centered on alterations to immunity, especially T cell-mediated immunity, in ageing, age-associated diseases and cancer in man and
the influence these have on the outcome of vaccination.
He is a Visiting Professor at Nottingham Trent University, UK, and at King´s College, London, U. He is an Honorary Professor at Manchester University, UK and
is on the Faculty of the Caner Solutions Program, Health Sciences North Research Institute, Sudbury, ON, Canada. He is a member of the Scientific Advisory Board for Repair Biotechnologies, Inc,
New York, USA. He is Co-Editor-in Chief of Cancer Immunology Immunotherapy, and of Immunity & Ageing, Deputy Editor of the Journal of Translational Medicine, Associate Editor of Mechanisms of
Ageing & Development, and on the Editorial Boards of J. Gerontology Series A, Age, Experimental Gerontology and Biogerontology. Total citations: 24102, H-index 87 (Google Scholar), average
citations per PubMed-listed articel, 49.0. He has coordinated three European Union collaborative programs on immunosenescence (EUCAMBIS, ImAginE and
T-CIA) and two on cancer vaccine research (EUCAPS, ESTDAB). He was an EU 5th Framework Program Expert Advisory Panel Member for Ageing and Public Health, 1997, and 7th FP Expert Consultant for
the ‘Road map for the future of ageing research in Europe’, 2007 as well as the 7th FP “WhyWeAge” 2010 consulting exercise to make recommendations on the priorities for European research on
ageing over the next decade. He was a member of the Sanofi-Pasteur-MSD and Sanofi-Aventis Advisory Boards on Immunosenescence and Vaccination, and of
the WHO Initiative for Vaccine Research Advisory Board on the Impact of Ageing on Vaccination, and of the
Seqirus Influenza Vaccines Advisory Board.